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Optimized Inhibitors of MDM2 via an Attempted Protein-
Templated Reductive Amination
Ramon van der Vlag+,[a] M. Yagiz Unver+,[a] Tommaso Felicetti+,[a, b]
Aleksandra Twarda-Clapa,[c] Fatima Kassim,[a] Cagdas Ermis,[a] Constantinos G. Neochoritis,[d, e]
Bogdan Musielak,[c] Beata Labuzek,[c] Alexander Dömling,[d] Tad A. Holak,[c] and
Anna K. H. Hirsch*[a, f, g]
Innovative and efficient hit-identification techniques are required to
accelerate drug discovery. Protein-templated fragment ligations
represent a promising strategy in early drug discovery, enabling the
target to assemble and select its binders from a pool of building
blocks. Development of new protein-templated reactions to access
a larger structural diversity and expansion of the variety of targets
to demonstrate the scope of the technique are of prime interest for
medicinal chemists. Herein, we present our attempts to use a
protein-templated reductive amination to target protein-protein
interactions (PPIs), a challenging class of drug targets. We address a
flexible pocket, which is difficult to achieve by structure-based drug
design. After careful analysis we did not find one of the possible
products in the kinetic target-guided synthesis (KTGS) approach,
however subsequent synthesis and biochemical evaluation of each
library member demonstrated that all the obtained molecules
inhibit MDM2. The most potent library member (Ki=0.095 μm)
identified is almost as active as Nutlin-3, a potent inhibitor of the
p53-MDM2 PPI.
Introduction
Discovery of fast and efficient techniques to identify bioactive
compounds constitutes an important part in today’s drug
discovery. A way to accelerate hit-identification is the use of
reversible reactions (dynamic combinatorial chemistry, DCC) or
irreversible reactions (kinetic target-guided synthesis, KTGS),
which are both categories of templated fragment ligations.[1] In
these templated fragment ligations, the target selects its own
inhibitors by assembling the corresponding binders from a
library of complementary building blocks or by binding and
amplifying them from a library of compounds formed in a
covalent bond-forming reaction. In KTGS, the biological target
accelerates the irreversible reaction between complementary
building blocks upon binding,[2,3] whereas in DCC a reversible
reaction between building blocks affords a dynamic combinato-
rial library (DCL) from which the biological target selects and
amplifies the best binder(s).[4,5] Both techniques hold the
potential to accelerate drug discovery and are still relatively
underexplored, especially in terms of target scope and avail-
ability of biocompatible reactions.
KTGS is a promising hit-identification strategy but only a
few reactions with a limited number of targets have been
reported so far.[1,2,6–19] The most widely used reaction is the
Huisgen 1,3-dipolar cycloaddition of azides and alkynes and
most work in KTGS focuses on acetylcholine esterase (AChE)
from various species, although different reactions and targets
have been explored.[2,3]
Protein-protein interactions (PPIs) are involved in many
biological functions, such as intercellular communication and
apoptosis. Targeting PPIs using small molecules is considered
challenging given the flatness of the interface, a lack of small-
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molecule starting points for the future design and the
difficulties in distinguishing real from artefactual binding.[20]
P53 is a tumor-suppressor protein that is activated by
cellular stress or damage and leads to cell-cycle arrest,
apoptosis and DNA repair. MDM2 is the negative regulator of
the p53 protein and its overexpression leads to loss of p53
function.[21,22] MDM2 has a well-defined and deep pocket,
unusual for PPIs, accommodating a hotspot triad consisting of
Trp23, Leu26 and Phe19 from p53.[21,23,24] Therefore, design of
high-affinity ligands to inhibit MDM2 should focus on these
hotspot amino acids of p53 (three-point pharmacophore
model). As a result, several small-molecule inhibitors have been
reported.[23–26] Some time ago, we found the Leu26 pocket to be
a flexible pocket, which is enlarged upon ligand binding (four-
point pharmacophore model).[27] Very recently, we expanded
this work with a thorough SAR analysis.[28] The flexibility of the
pocket makes it very difficult to target using structure-based
drug design (SBDD) or other computational techniques such as
virtual screening. Therefore, KTGS holds the potential to explore
this flexible binding pocket by letting the protein select which
combination of building blocks ideally fits.
Use of protein-templated reactions to interrupt PPIs has
only been shown for the Bcl-XL/BAK interaction[11,17] and the 14-
3-3 protein.[7] These targets feature deep cavities in the binding
pocket, which makes them suitable for KTGS just like MDM2.
The reactions used for these two targets are the sulfo-click
reaction between thio acids and sulfonyl azides and SN2 thiol
ring opening of epoxides, respectively.
The reversible reaction between an aldehyde and an amine
to afford imines has been widely applied in DCC to target
various biological targets (Figure 1).[29–39] It is generally believed
that the assembly of inhibitors is achieved by simultaneous
binding of both building blocks in adjacent pockets, followed
by imine formation and subsequent reduction, resulting in an
irreversible amine bond. However, since in most cases the
reducing agent is present in the mixture during most of the
reaction time, it is unknown if this is actually true and difficult, if
not impossible, to prove. Additionally, we think that protein-
templated reductive amination is an example of KTGS instead
of genuine DCC, in which the formed bond remains non-
covalent.
Since the formed imines are unstable in aqueous media,
in situ reduction is performed in most cases. After analysis,
frequently only the most amplified hits are synthesized and
tested for activity. This approach, however, represents several
pitfalls, such as: 1) it is assumed that the imines have a similar
binding mode as the amines; and 2) the potency of the
compound might change upon reduction. Previously, large
differences in potency between imine and amine have been
reported.[31,39] Furthermore, we noticed that in most reports the
potencies of the starting materials are not reported, although
many of the starting materials are used as anchors.
Herein, we present our efforts to use protein-templated
reductive amination in the KTGS context for the identification
of inhibitors of the MDM2-p53 PPI. Additionally, it is the first
application of KTGS to address a flexible binding pocket (Leu26
pocket). Given that we were unable to observe any of the
reductive amination products, we evaluated all members of the
library.
Results and Discussion
After the discovery of the extended Leu26 pocket in MDM2,[27]
we set out to explore this flexible pocket. Having selected
MDM2 as a target, we designed our potential inhibitor scaffold
starting from the X-ray crystal structure of inhibitor 1 in
complex with MDM2 (Figure 2, PDB ID: 4MDN).[27]
We designed and optimized a new inhibitor by using the
molecular modeling program SeeSAR.[40] Inhibitor 1 occupies
the three sub-pockets of MDM2 that are named according to
the corresponding p53 residues: the 6-chloroindole-2-hydroxa-
mic acid moiety is hosted by the Trp23 pocket, the tert-butyl
group occupies the Phe19 pocket and the large 4-clorobenzyl
phenyl ether was found to fill the Leu26 and an induced sub-
pocket. In order to occupy this extended sub-pocket in an
Figure 1. Protein-templated reductive amination.
Figure 2. (Top) X-ray crystal structure of MDM2 in complex with docked
inhibitor 1 (pink), superimposed with designed inhibitor 2 (green) (PDB ID:
4MDN). Oxygen, nitrogen and chlorine atoms are shown in red, blue and
light green, respectively. (Bottom) Design of inhibitor 2 as a product of
reductive amination, based on the previously reported inhibitor 1.
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optimal way by using the reductive amination reaction, we
converted the 4-chlorobenzyl ether moiety into an amine,
which can be assembled from the corresponding aldehyde 3
and amine 4 followed by in situ reduction (Scheme 1).
Following the design of the initial inhibitor, we generated a
combinatorial library by using aldehyde 3 as a core scaffold and
eight different amines (4–11) to explore and fill the extended
Leu26 pocket in the best manner and give rise to a focused SAR
(Scheme 1).
The use of KTGS to fill flexible pockets is unprecedented. To
explore this binding pocket and possibly open-up the Leu26
pocket even further, we used a benzyl- and naphthyl-amine in
the library in addition to the aromatic amines to extend the
length of the linker between the core scaffold and the amines.
A potential extension reaching deeper into the pocket would
be an important finding for future drug development.
Having selected the building blocks from commercially
available amines, we synthesized the core scaffold 3 as shown
in Scheme 2. Literature protocols afforded compounds 12 and
13, in three and one step(s), respectively.[41,42] A four-component
Ugi reaction of aldehyde 12, amine 13, formic acid (14) and
tert-butyl-isocyanide (15) furnished the corresponding Ugi
product 16 in 63% yield. Oxidation of the alcohol and
subsequent hydrolysis of the ester led to the final aldehyde 3 in
86% yield over two steps.
Biochemical evaluation of aldehyde building block 3
showed promising potency against MDM2 (Ki=0.55�0.05 μm).
We envisioned that additional interactions in the flexible pocket
would enhance compound potency. Therefore, we set up two
experiments in parallel using the synthesized aldehyde building
block and eight different commercially available amines (4–11),
a protein-templated reaction and a blank reaction at pH=7.4
(100 mm phosphate buffer, 10% DMSO).
In both reactions, we applied standard building block and
reducing agent concentrations of 100 and 200 μm, respectively.
One of the stringent requirements for KTGS is a substantial
difference in reaction rate between the blank and the protein-
templated reaction. As the imine formation between an
aldehyde and an amine is fast, we used dilute conditions to
prevent product formation in the reference reaction for a
certain time.[43] As a result, less protein is required, an important
consideration especially for precious proteins. By using a
reducing agent in the reaction mixture from the beginning,
formed imines would be “frozen” by reduction, leading to
detectable amounts of products. Therefore, the two reactions
were started by mixing all amines 4–11 (100 μm each),
aldehyde 3 (100 μm) and NaCNBH3 (200 μm). To the protein-
templated reaction, we added MDM2 (100 μm). Then, both
reactions were carefully monitored using UPLC-MS analysis
(wavelengths: 254 and 305 nm) for two days. After two days,
signs of denaturation were observed in all MDM2-containing
samples. We did not detect any trace of one of the reductive
amination products, while a large amount of the starting
materials were observed. Additionally, experiments in which
MDM2 was replaced by bovine serum albumin (BSA), experi-
ments without reducing agent and experiments in which the
potent MDM2 inhibitor Nutlin-3 (100 μm, Ki=36 nm
[44]) was
added, showed identical results (Figures S10 and S11). In order
to estimate how much of the product(s) should be formed for
detection, we assessed the detection limit of the UPLC-MS. The
UV-visible spectrum of 3 showed a clear absorption band
around 305 nm (Figure S12). This wavelength has the benefit
over 254 nm that there is a lot less background signal. Under
identical conditions as the protein-templated reaction, the
detection limit of aldehyde 3 was estimated to be <2.6 μm and
<0.88 μm for 254 and 305 nm, respectively (Figures S13–15). In
case only one reductive amination product were formed and
taking into account the protein denaturation step with
acetonitrile, this would correspond to as low as 1.8%
conversion at 305 nm. Even if all eight amines reacted in a
similar fashion, generating all possible products, this would
require only 14% conversion of 3. We believe that in order to
claim a protein-templated reaction, we should be far above
these numbers.
Scheme 1. Selection of building blocks for the protein-templated reductive
amination, which affords eight possible amine products.
Scheme 2. Synthesis of aldehyde building block 3. Conditions and reagents:
i) three-step synthesis[41] ii) one-step synthesis[42] iii) MeOH, rt, 6 d, 63%; iv) a)
DMP, CH2Cl2, rt, 3 h, b) 1 m LiOH, H2O-EtOH (1 :1), rt, 18 h, 86%.
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In order to determine the potency of each product we
synthesized all possible products (2 and 17–23, Table 1),
starting from the core scaffold 3 by using a reductive amination
protocol (Scheme 3).
We evaluated the inhibitory potency of compounds 2 and
17–23 by using the fluorescence polarization assay, as pre-
viously described.[45] MDMX is another p53 binding protein and
shows significant homology with MDM2. In order to investigate
if the compounds selectively inhibit one of the proteins, we
tested all compounds against MDM2 and MDMX (Table 1).
As can be seen from Table 1, the majority of the compounds
(2 and 17–21, Ki=0.40–0.76 μm) show an activity against
MDM2 in the same range as aldehyde 3 (Ki=0.55�0.05 μm)
and parent compound 1 (Ki=0.60 μm).[27] Amine 23 (Ki=3.18�
0.18 μm) is almost six-fold less potent than aldehyde 3.
Interestingly, 18 (Ki=0.63�0.07 μm) is three times more potent
than its regioisomer in which the CH2  NH is reversed (Ki=
1.9 μm).[28] Surprisingly, compound 22 shows a Ki value of
0.095�0.010 μm, which makes it by far the most potent
inhibitor of this series. In fact, the compound is almost as
potent against MDM2 as Nutlin-3 (Ki=0.036�0.009 μm
[44]).
The inhibitory activities of the synthesized reductive amina-
tion products against MDMX are rather comparable (Ki=3.73–
7.08 μm). Except for compound 17 which has a slightly higher Ki
of 12.2�2.1 μm and 23, which is not active against MDMX
under the applied conditions. Aldehyde 3 (Ki=11.4�1.6 μm)
also has a reduced inhibitory activity against MDMX in
comparison to MDM2. Most compounds have a preference for
MDM2 by a factor 7–16. With a selectivity factor of 21, aldehyde
3 is slightly more selective for MDM2 than most of the amines.
A remarkable exception is compound 22, which is over four
times more selective for MDM2 than inhibitors 2 and 18–21 and
two times more selective than aldehyde 3. Although the activity
of 22 against MDM2 is close to the Ki value of Nutlin-3, it is
around six times less selective.
There are several possible explanations as to why we did
not find any of the reductive amination products in the protein-
templated experiments. Very recently, Van der Veken and co-
workers reported their efforts toward the application of the
Groebke-Blackburn-Bienaymé three-component reaction in
KTGS.[46] The imine formation under near-physiological condi-
tions proved to be most challenging. Furthermore, although
their final products were also very potent against the protein
target, the target itself interfered with the attempted reaction,
Table 1. Biochemical evaluation of all reductive amination products.
Inhibitor Ki [μm]
MDM2
Ki [μm]
MDMX
Selectivity
MDMX/MDM2
3 Aldehyde 0.55�0.05 11.4�1.6 21�3.5
2 0.40�0.05 4.18�0.27 10�1.5
17 0.76�0.08 12.2�2.2 16�3.4
18 0.63�0.07 4.56�0.49 7.2�1.1
19 0.75�0.08 7.08�0.52 9.4�1.2
20 0.47�0.04 3.73�0.30 7.9�0.9
21 0.49�0.04 4.61�0.39 9.4�1.1
22 0.095�0.010 3.95�0.46 42�6.5
23 3.18�0.18 >15 �5
Nutlin-3[44] 0.036�0.009 9.38�0.35 261�66
Experiments were performed in duplicate and values are reported as average � standard deviation. Note: at physiological pH, there is a difference in charge
expected between the aniline-type products and benzylamine-type compounds 17 and 23.
Scheme 3. Synthesis of the inhibitors 2 and 17–23. (a) Conditions and
reagents: amines 4–11, pyrrolidine, 4 Å MS, Na(CH3CO2)3BH, dry CH2Cl2, rt,
18 h.
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which could also be the case in our study. Additionally, it could
be that the reducing agent does not reach the imine, which is
therefore hydrolyzed upon analysis. Last, there are clear differ-
ences in rigidity and hydrogen-bond donor/acceptor profiles
between the imines and the amines. It can well be that the
aldehyde and reductive amination products show activity
against MDM2, but that the imines cannot be formed or do not
fit in the active site. We performed crystallization studies to
confirm the binding mode of the new inhibitors, but due to
solubility problems we could not obtain any crystals.
To confirm the inhibitory activity of the compounds further,
the uniformly 15N-labeled MDM2 was titrated with an increasing
concentration of compound 17, and 1H-15N HSQC spectra were
recorded after each new portion of the inhibitor was added.
Instead of the most potent compound, 22, compound 17 was
used due to its better solubility. The method is based on
monitoring changes in NMR chemical shifts in protein amide
backbone resonances upon its interaction with a small
molecule.[47–50] In the course of titration, shifts or disappearances
of cross-peaks assigned to the amino acids of MDM2 affected
by binding of 17 were observed, which corroborates the
binding event (Figure 3).
Conclusions
In conclusion, herein, we reported our efforts toward the first
example of a reductive amination in KTGS applied to a PPI
target. By using our target MDM2 in situ, we screened a library
of compounds in one-pot, which did not reveal a clear hit over
a course of two days. After synthesis of all library members, we
found a very potent and rather selective inhibitor of MDM2
(Ki=0.095�0.010 μm). Although, the KTGS method can find
application in the early stages of drug discovery, one should be
careful in the use of imine-based chemistry. Particularly
interesting scenarios for the use of KTGS in drug discovery are
flexible protein pockets that are difficult to target by structure-
based approaches.
Experimental Section
Detailed descriptions of the synthetic and biological procedures are
provided in the Supporting Information.
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